Mainz Biomed unveils key findings from eAArly DETECT study

Mainz Biomed unveiled key findings from its eAArly DETECT study during a poster presentation at the renowned Digestive Disease Week, DDW, 2024 in Washington D.C. The Company was awarded as a Poster of Distinction by the Digestive Disease Week judges. The poster titled ‘Novel Stool-based non-invasive early detection of colorectal cancer and precancerous lesions by classic FIT combined with nucleic acid-based biomarker signatures’ was presented by Dr. Lena Krammes, Senior Scientist at Mainz Biomed. Key findings of the eAArly DETECT clinical study include a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%. Additionally, the data demonstrated that within the advanced precancerous lesion patients, 100% of those patients with high grade dysplasia were detected. Only one of the colorectal cancer patients was not detected at stage I of the disease. Resulting performance data confirms the outcome previously obtained from the separate European ColoFuture study and that this multimodal screening strategy reflects a substantial and meaningful improvement for CRC and especially AA detection, where improved sensitivity is urgently needed to decrease CRC incidence and mortality